| (Values in U.S. Thousands) | Jun, 2016 | Mar, 2016 | Dec, 2015 | Sep, 2015 | Jun, 2015 |
| Sales | -9,999,000 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -9,999,000 | -490 | -1,140 | -1,370 | -1,530 |
| Net Income Growth | -2,040,512.24% | +57.02% | +16.79% | +10.46% | +16.85% |
Genspera Inc (GNSZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
GenSpera Inc. is a biotechnology company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including prostate, liver, brain and other cancers. Its prodrug development candidates include: G-202 in Phase II clinical trial for the blood vessels of various solid tumors primarily liver cancer; G-114, G-115 and G-301 for the treatment of prostate cancers. GenSpera Inc. is based in San Antonio, Texas.